Last $5.83 USD
Change Today -- / -0.85%
Volume 20.0K
ICAD On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 06/17/13 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Snapshot

Open
$5.85
Previous Close
$5.88
Day High
$5.85
Day Low
$5.75
52 Week High
02/20/13 - $6.90
52 Week Low
07/27/12 - $1.75
Market Cap
63.2M
Average Volume 10 Days
26.3K
EPS TTM
$-0.75
Shares Outstanding
10.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICAD INC (ICAD)

Related News

No related news articles were found.

icad inc (ICAD) Related Businessweek News

No Related Businessweek News Found

icad inc (ICAD) Details

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy that enable healthcare professionals and radiologists to identify pathologies and pinpoint cancer earlier. It offers Axxent eBx system, which is used for the treatment of early stage breast cancer, endometrial cancer, and skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated. It also provides computer-aided detection (CAD) solutions for digital and film-based mammography systems, including SecondLook systems that detects and identifies masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to PACS and/or review workstations. In addition, the company offers image analysis and workflow solutions in MRI imaging comprising SpectraLook for breast, VividLook for prostate, and OmniLook for other organs; and VersaVue Enterprise, a review and reporting solution, which provides visual and quantitative depictions of the movement of contrast agent through a lesion. Further, it provides VeraLook that supports the detection of colonic polyps in conjunction with CT Colonography; and the TotalLook MammoAdvantage system, a mammography specific digitizer. The company sells its products to hospitals, ambulatory care centers, and free standing radiation oncology facilities. It sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.

101 Employees
Last Reported Date: 02/27/13
Founded in 1984

icad inc (ICAD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $398.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $267.9K
Senior Vice President of Research and Develop...
Total Annual Compensation: $223.0K
Senior Vice President of Marketing and Strate...
Total Annual Compensation: $243.9K
Compensation as of Fiscal Year 2012.

icad inc (ICAD) Key Developments

iCAD, Inc. Approves Amendment to Certificate of Incorporation

On May 20, 2013, iCAD, Inc. adjourned its annual meeting to provide its stockholders additional time to vote on proposal 2, which related to the amendment to its certificate of incorporation. The charter amendment requires the affirmative vote of the holders of a majority of all shares outstanding for adoption. On May 31, 2013, the Company reconvened its 2013 annual meeting of stockholders. The Certificate of Incorporation of the Corporation is hereby amended by striking out the first sentence of Article FOURTH thereof and by substituting in lieu thereof a new first sentence reading as follows: FOURTH: The total number of shares of capital stock which the Corporation shall have authority to issue is Twenty One Million (21,000,000), of which Twenty Million (20,000,000) shares shall be Common Stock, par value $0.01 per share (Common Stock), and One Million (1,000,000) shares shall be Preferred Stock, par value $0.01 per share (Preferred Stock). That such amendment has been duly adopted in accordance with the provisions of the General Corporation Law of the State of Delaware by the affirmative vote of the holders of a majority of the stock entitled to vote at a meeting of stockholders.

iCAD, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

iCAD, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenue of USD 7.930 million compared to USD 6.343 million a year ago. Loss from operations was USD 0.328 million compared to USD 2.026 million a year ago. Loss before income tax expense was USD 0.717 million compared to USD 2.253 million a year ago. Net loss and comprehensive loss was USD 0.727 million compared to USD 2.264 million a year ago. Basic and diluted loss per share was USD 0.07 compared to USD 0.21 a year ago. Non GAAP adjusted EBITDA was USD 0.592 million compared to non GAAP adjusted LBITDA of USD 0.967 million a year ago. Non GAAP adjusted net loss was USD 1.158 million compared to USD 2.783 million a year ago. Non GAAP adjusted net loss per share was USD 0.11 compared to USD 0.26 a year ago.

iCAD, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 12:10 PM

iCAD, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 12:10 PM. Venue: The Westin Grand Central Hotel, 212 East 42nd Street, New York, New York, United States. Speakers: Kenneth M. Ferry, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $5.83 USD --

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $21.43 USD +0.15
Merge Healthcare Inc $3.63 USD +0.06
MGT Capital Investments Inc $4.80 USD +0.14
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit www.icadmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.